Unlocking The Potential Of Autologous Cell & Gene Therapy Through Digital Transformation

By Madalina Miron, Emerson

Autologous and personalized cell and gene therapies (CGTs) are redefining the boundaries of modern medicine, offering curative potential for previously untreatable conditions. Yet, scaling these therapies presents a unique set of challenges for life sciences manufacturers—from managing patient-specific batches to maintaining strict regulatory compliance and data integrity. Unlike traditional pharmaceuticals, CGTs demand a scale-out approach and digital precision. Forward-looking organizations are turning to intelligent automation, real-time analytics, and digital batch records to streamline production and ensure vein-to-vein traceability.

Explore how emerging technologies like AI and digital twins are playing a pivotal role in optimizing processes and supporting critical decisions.